

## Participant Demographics and Baseline Characteristics

	RAL 1200 mg QD <sup>a</sup> (n=531)	RAL 400 mg BID <sup>a</sup> (n=266)	Total (N=797)
Male, n (%)	440 (82.9)	234 (88.0)	674 (84.6)
Race, n (%)			
White	301 (56.7)	172 (64.7)	473 (59.3)
Black or African American	98 (18.5)	36 (13.5)	134 (16.8)
Asian	83 (15.6)	40 (15.0)	123 (15.4)
Multiple	46 (8.7)	14 (5.3)	60 (7.5)
Other <sup>b</sup>	3 (0.6)	4 (1.5)	7 (0.9)
Hispanic or Latino Ethnicity, n (%)	126 (23.7)	52 (19.5)	178 (22.3)
Age in years, mean (SD) [min, max]	35.4 (10.3) [18, 66]	36.9 (11.0) [19, 84]	35.9 (10.5) [18, 84]
History of AIDS, n (%)	79 (14.9)	29 (10.9)	108 (13.6)
HIV-1 subtype B, n (%)	335 (63.1)	186 (69.9)	521 (65.4)
Hepatitis B and/or C positive <sup>c</sup> , n (%)	15 (2.8)	8 (3.0)	23 (2.9)
Baseline HIV-1 RNA			
log <sub>10</sub> copies/mL, mean (SD)	4.6 (0.7)	4.6 (0.7)	4.6 (0.7)
>100,000 copies/mL, n (%)	149 (28.1)	77 (28.9)	226 (28.4)
>500,000 copies/mL, n (%)	25 (4.7)	15 (5.6)	40 (5.0)
Baseline CD4+ T-cell count			
Cells/μL, mean (SD)	407.6 (213.7)	428.9 (217.3)	414.7 (215.0)
<200 cells/mm <sup>3</sup> , n (%)	69 (13.0)	37 (13.9)	106 (13.2)
<50 cells/mm <sup>3</sup> , n (%)	9 (1.7)	6 (2.3)	15 (1.9)

<sup>a</sup> In combination with FTC/TDF once daily.

<sup>b</sup> Other races include American Indian, Alaska Native, Native Hawaiian, or Other Pacific Islander.

<sup>c</sup> Evidence of hepatitis B surface antigen and/or HCV RNA.